New From The Freedonia Group: US Vaccines Demand to Reach $7.4 Billion in 2008 Business Wire
click here to return to Business Wire main menu
DonateNow





New From The Freedonia Group: US Vaccines Demand to Reach $7.4 Billion in 2008

Business Wire - October 7, 2004

CLEVELAND -- Demand for vaccines in the US will advance 8.6 percent annually to $7.4 billion in 2008. Afterwards, new products for complex human diseases will lead to rapid acceleration in growth. Within the next few years, advances in biotechnology and related life sciences are expected to bring the first vaccines for AIDS, cancer, genital herpes and West Nile virus into the US marketplace. By the end of the decade, several additional preparations will be approved for preventing these diseases, contributing vast improvements to health standards. By 2013, developmental vaccines for human indications not presently served will generate demand of $9.1 billion, making up nearly half of industry revenues. Cancer vaccines alone are projected to reach demand of $6 billion in 2013, accounting for 35 percent of the human vaccines market.

Through 2008, pediatric preparations will remain the top-selling group of vaccines based on well-established efficacy, improving formulations and a large number of potential new patients. About 40 percent of US children are not fully immunized in line with recommended schedules. Attempts to extend coverage to a larger percentage of children will boost growth opportunities for pediatric vaccines.

Influenza vaccines will generate strong growth opportunities, with annual shots recommended for most individuals and new formulations extending product availability. The introduction of new SARS preparations will underlie the above average sales gains projected for travel vaccines. Among other presently available human vaccines, preparations against meningococcal infections will see the fastest growth in demand, spurred by the commercialization of new, more effective preparations.

Based on a large potential patient base, hepatitis preparations will continue to generate the second-largest sales volume among vaccines through 2008. However, growth opportunities for these products will slow due to shifting demographic patterns. The decline in the 5 to 14 years old population segment will weaken sales increases generated by hepatitis A vaccines. The decreasing number of unvaccinated adults, attributable largely to the previous immunization of health care workers, will soften growth in demand for hepatitis B vaccines.

CONTACT: The Freedonia Group

Corinne Gangloff, 440-684-9600

pr@freedoniagroup.com

SOURCE: The Freedonia Group


041007
BW041004

Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .